HemoGenyx Pharmaceuticals PLC (LONHEMO) chief Dr Vladislav Sandler is set to present at a cancer immunotherapy conference in March.
At the Keystone Symposia on Molecular and Cellular Biology in Canada, he will provide an overview of the development of the company's CDX antibodies.
Specifically, he will assess the potential benefit of using these antibodies for the treatment of acute myeloid leukaemia (AML) as well as the conditioning of patients for hematopoietic stem cell transplantation.
Sandler’s address will go on to highlight the fact that, despite numerous advances in understanding AML, treatment remains “unsatisfactory” and that relapsed or refractory forms of the disease are nearly always fatal.
The conference takes place in the winter resort of Whistler from March 10 to 14.
In late afternoon trading, shares in Hemogenyx were 1.6% higher at 3.25p.
In a note to clients, analysts at ‘house’ broker Northland Capital commented: “This conference is a good arena to showcase Hemogenyx’s novel therapies, as it brings together leading experts in the cancer immunotherapy sector.”
For more details click here.
-- Adds share price, analyst comment --